BioSpace News Archive

Elevation Oncology, Inc. announced the appointments of Julie Cherrington, Ph.D. and Alan Sandler, M.D., to its Board of Directors.

Arrowhead Pharmaceuticals, Inc. announced that it is scheduled to participate in the following upcoming events.

Apyx® Medical Corporation (NASDAQ:APYX) (the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced that financial results for the fourth quarter and fiscal year 2023 will be released before the market opens on Thursday, March 21st.

Neurogene Inc. today announced the expansion of its ongoing Phase 1/2 gene therapy clinical trial for NGN-401 for female pediatric patients with Rett syndrome and updates to enable more rapid enrollment in the trial.

MoonLake Immunotherapeutics (“MoonLake”; Nasdaq: MLTX) today announced that 24-week data from its Phase 2 MIRA trial with the Nanobody sonelokimab in moderate to severe hidradenitis suppurativa (HS), will be presented in a late breaking oral session on March 10 at 14:00 PST at the 2024 American Academy of Dermatology (AAD) Annual Meeting.

GenSight Biologics announced that new scientific data and analyses on the gene therapy LUMEVOQ® will be presented at the 50th Annual Meeting of the North American Neuro-Ophthalmology Society in Honolulu, Hawaii.

CytoMed Therapeutics Limited announced that it has entered into a Research Collaboration Agreement with Sengkang General Hospital Pte Ltd, a public hospital in Singapore and a member of the SingHealth group to establish proof-of-concept use of an injectable cartilage regeneration therapy that has been developed with donor-sourced, umbilical cord-derived mesenchymal stem cells to treat cartilage injury.

ANEW MEDICAL, INC. announced that is has been granted and issued a patent in China, number CN 117126829 A for the use of ANEW’s Klotho protein and Klotho gene delivery and expression systems in the treatment of cognition, memory and neurodegenerative diseases.

RadNet, Inc. announced that Mark Stolper, Executive Vice President and Chief Financial Officer will be presenting at the Raymond James 45th Annual Institutional Investors Conference in Orlando, Florida today, Monday, March 4, 2024 at 3:25 p.m. Eastern Time.

AbTherx announced expanded commercialization of its bispecific and full human diversity antibody discovery technologies.